Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07467213
PHASE3

Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute Myocardial Infarction

Sponsor: Samsung Medical Center

View on ClinicalTrials.gov

Summary

This study aims to compare the clinical outcomes between routine use of potassium competitive acid blocker (P-CAB) and guideline-directed gastrointestinal (GI) protection strategy in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) and being treated with dual antiplatelet therapy (DAPT).

Official title: Routine Use of Potassium Competitive Acid Blocker Versus Guideline-Directed Gastrointestinal Protection Strategy in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention on Dual Antiplatelet Therapy: A Randomized Trial

Key Details

Gender

All

Age Range

19 Years - Any

Study Type

INTERVENTIONAL

Enrollment

5000

Start Date

2026-06-23

Completion Date

2030-12-31

Last Updated

2026-06-26

Healthy Volunteers

No

Interventions

DRUG

Zastaprazan

Zastaprazan citrate 20mg will be administered orally once daily for gastrointestinal protection according to the study protocol.

DRUG

Proton Pump Inhibitors (PPI)

Guideline-directed gastrointestinal protection using various proton pump inhibitors as determined by the physician.

Locations (1)

Samsung Medical center

Seoul, South Korea